Mallinckrodt gains tax incentives in Singapore
The office of Mallinckrodt’s regional Asia/Pacific headquarters in Singapore has been awarded “business headquarters” status by the Singapore Economic Development Board.Mallinckrodt’s business tax rate will be reduced to 13% from
The office of Mallinckrodts regional Asia/Pacific headquarters in Singapore has been awarded business headquarters status by the Singapore Economic Development Board.
Mallinckrodts business tax rate will be reduced to 13% from 25% for the five years of the status, said Robert Martsching, Mallinckrodt investor spokesman. The business development designation was awarded in recognition of the pharmaceutical and medical imaging companys commitment to regional business growth.
Singapore business development officials say they hope to establish Mallinckrodt as one of the most dynamic and fastest growing healthcare companies in the Asia/Pacific region. Mallinckrodts regional headquarters in Singapore has 34 employees and is headed by Kin Chua, president of Mallinckrodt Asia/Pacific.
Staff members provide marketing, technical, financial, and administrative support to Mallinckrodt offices and employees throughout the Pacific Rim, including Australia, China, Hong Kong, India, Korea, Japan, and Taiwan. Mallinckrodts Singapore office has established a clinical education center to enhance the technical skills of providers, distributors, and employees.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
